sermorelin
Trade name: geref
Approved
Dec 28, 1990
Sermorelin, a 29 amino acid analog of human growth hormone-releasing hormone (GHRH), is the shortest synthetic peptide with a full biological activity of GHRH which is used as a diagnostic agent to assess growth hormone (GH) secretion for the purpose of diagnosing growth hormone deficiency. Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary. Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion. Hormone responses to intravenous sermorelin appear to be a rapid and relatively specific test for the diagnosis of growth hormone deficiency. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Timeline
1980s
- Sep 14, 1988
Orphan Drug Designation
1990s
- Dec 28, 1990
Merck Serono — Earliest FDA Approval
- Dec 28, 1990
Merck Serono — NDA Organization
- Dec 28, 1990
Merck Serono — NDA Secondary Org
Indications
Approved for
Mechanism of action
GHRHR agonist
It's an analogue of GHRH, which seems to be used as diagnostic of growth hormone deficiency, but also as a replacement therapy in children
Approval history
- approvedDec 28, 1990
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaSermorelin ↗
- NCATS89243S03TE ↗
- ChEMBLCHEMBL1201490 ↗
Also known as
- geref
- geref
- geref
- sermorelin
- sermorelin
- sermorelin
- sermorelin
- sermorelin
- sermorelin
- sermorelin
- sermorelin acetate
- sermorelin acetate
- sermorelin acetate
- sermorelin acetate
- sermorelin acetate
- sermorelin acetate
- sermorelin acetate
- somatoliberin
Organizations
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Merck Serono | For profit | NDA | Dec 28, 1990 |
| Merck Serono | For profit | NDA2 | Dec 28, 1990 |
| Merck Serono | For profit | SYN | Sep 26, 1997 |